2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 899

Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout
Abstract Number: 668

Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
Abstract Number: 2508

Large Joint and Lower Extremity Involvement Has Higher Impact on Disease Outcomes in Oligoarticular PsA
Abstract Number: 2043

Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Abstract Number: 2655

Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment
Abstract Number: 268

LARS Study: Latin American Rheumatologist Survey
Abstract Number: 1613

LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis
Abstract Number: 164

Learner Practice Gaps in Osteoporosis: Piloting a Metabolic Bone Disease Curriculum Within a Fracture Liaison Service Framework
Abstract Number: 1096

Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks
Abstract Number: 2248

Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease
Abstract Number: 1357

Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity
Abstract Number: 2336

Levels of Proinflammatory Cytokines in Rheumatoid Arthritis Patients with Carotid Plaque: A Case-Control Study
Abstract Number: 1139

Lifetime Direct Medical and Indirect Cost of Knee Osteoarthritis: Impact of Pain and Structural Severity
Abstract Number: 978

Light Mediated Therapeutics in Arthritis
Abstract Number: 74

LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies
Abstract Number: 1527

Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Abstract Number: 2851

Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Abstract Number: 1225

Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound
Abstract Number: 1659

Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
Abstract Number: 1288

Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Abstract Number: 989

Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis
Abstract Number: 2808

Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block
Abstract Number: 1032

Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation
Abstract Number: 41

Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations
Abstract Number: PP02

Living and Adjusting to a Diagnosis of Rheumatoid Arthritis (RA) with an Interdisciplinary Team
Abstract Number: 574

Localization and Morphology of Magnetic Resonance Imaging Features of Pathologic Changes in the Sacroiliac Joints Suggestive of Axial Spondyloarthritis – a Systematic Comparison of Patients and Controls with Chronic Back Pain
Abstract Number: 469

Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Abstract Number: 2749

Long Non-coding RNA HOTAIR Induces Myofibroblast Activation in Systemic Sclerosis Through EZH2 Dependent De-repression of NOTCH Signalling Pathway Activation
Abstract Number: 1667

Long Term Outcome of Hydralazine-Associated Vasculitis
Abstract Number: 2716

Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Abstract Number: 2893

Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation
Abstract Number: 757

Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Abstract Number: 1491

Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Abstract Number: 1542

Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Abstract Number: 1417

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Abstract Number: 1543

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry
Abstract Number: 2696

Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 251

Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US
Abstract Number: 1692

Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice
Abstract Number: 376

Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study
Abstract Number: 859

Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
Abstract Number: 1814

Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Abstract Number: 2717

Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Abstract Number: 808

Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
Abstract Number: 1733

Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort
Abstract Number: 538

Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
Abstract Number: 1534

Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Abstract Number: 2145

Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Abstract Number: 2347

Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center
Abstract Number: 1520

Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Abstract Number: 1506

Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results
Abstract Number: 508

Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Abstract Number: 591

Longitudinal Assessment of MRI of the Sacroiliac Joints in the ASAS Classification Cohort: Evolution of Diagnostic Features and Predictive Utility for Axial Spondyloarthritis
Abstract Number: 2592

Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care
Abstract Number: 679

Longitudinal Changes in Manifestations of SLE
Abstract Number: 2788

Longitudinal Changes in the Nasal Microbiome and Disease Activity in Patients with Granulomatosis with Polyangiitis
Abstract Number: 438

Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?
Abstract Number: 638

Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus
Abstract Number: 357

Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification
Abstract Number: 1363

Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?
Abstract Number: 716

Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients
Abstract Number: 891

Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation
Abstract Number: 1131

Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?
Abstract Number: 2014

Loss-of-function of the DNA Repair Nuclease MRE11A Induces Mitochondrial Failure and Tissue Inflammation in Rheumatoid Arthritis
Abstract Number: 2413

LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
Abstract Number: 1734

Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Abstract Number: 97

Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis
Abstract Number: 1387

Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Abstract Number: 1152

Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
Abstract Number: 2531

Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Abstract Number: 950

Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease
Abstract Number: 505

Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Abstract Number: 2815

Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus
Abstract Number: 2164

Lumbar Spinal Stenosis in Patients with Wild-type Transthyretin Cardiac Amyloidosis
Abstract Number: 1628

Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Abstract Number: 2861

Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
Abstract Number: 1028

Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits
Abstract Number: 1111

Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients
Abstract Number: 1062

Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1575

Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Abstract Number: 2312

Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Abstract Number: 61

Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency
Abstract Number: 2817

Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis
Abstract Number: 1024

Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].